多菌灵人工抗原的合成及其鼠源性多克隆抗体的制备

目的 合成多菌灵人工抗原,制备多菌灵多克隆抗体并鉴定其特性。方法 利用混合酸酐法引入羧基制备多菌灵半抗原。将小分子半抗原与大分子载体牛血清白蛋白(BSA)和卵清蛋白(OVA)偶联合成多菌灵人工抗原和包被抗原,利用聚丙烯酰胺凝胶电泳(SDS-PAGE)对人工抗原进行鉴定。用制备的人工抗原免疫小鼠获得抗多菌灵多克隆抗体,利用间接ELISA对抗体效价以及特异性进行测定。结果 成功制备多菌灵人工抗原。免疫小鼠后获得的抗体效价可达1∶12 800。抗体对多菌灵的半数抑制剂量(IC₅₀)为0.107μg/mL,且与苯菌灵、噻菌灵的交叉反应率均<1%。结论 成功获得高敏感性、高特异性的多克隆抗体,为多菌灵残留快速检测方法的建立奠定了基础。     

恩诺沙星完全抗原的制备试验

目的制备恩诺沙星(EF)的完全抗原,进而为EF单克隆抗体检测试剂盒的研制奠定基础。方法将小分子的药物EF和鸡血清白蛋白(OVA)以及牛血清白蛋白(BSA)分别采用碳二亚胺法和活化酯法两种不同的偶联方法合成完全抗原,通过紫外特征光谱和抗血清效价对完全抗原的合成效果进行分析。结果2种不同的偶联方法均使OVA和BSA与EF偶联成功。偶联方法对于完全抗原的合成效果也存在差异,从紫外吸光率和偶联物结合比判断,OVA采用活化酯法效果好,未经EDA处理的OVA、活化酯法和碳二亚胺法合成的偶联物的结合比分别为10.3、20.7、16.5;而BSA采用碳二亚胺法效果好,未经EDA处理的BSA、活化酯法和碳二亚胺法合成的偶联物的结合比分别为20.5、24.6和30.8。血清效价检测发现,以BSA-EF为完全抗原的效价为25600,以OVA-EF为完全抗原的效价为6400,这表明完全抗原的合成是成功的。结论2种不同方法合成的OVA-EF和BSA-EF完全抗原,可以作为免疫原用于制备抗体以及检测时的包被原进行ELISA检测。     

PCB77人工抗原的合成及多克隆抗体的制备

目的:制备PCB77人工抗原和多克隆抗体,为建立其免疫学检测方法提供技术准备。方法:以3,4-二氯苯基乙酸为半抗原,在低温和弱碱性条件下,采用N-羟基琥珀酰亚胺活性酯法将其与载体BSA偶联,制备PCB77的人工抗原,计算结合比为23∶1,免疫家兔获得了PCB77的多克隆抗体。采用混合酸酐法将半抗原与OVA偶联,结合比为8∶1,用作ELISA检测包被原。间接ELISA检测结果表明,2只兔子的抗血清效价均达1∶20 000以上。抗血清经辛酸-硫酸铵沉淀法纯化后通过ELISA检测验证了PCB77人工抗原的有效性,通过方阵滴定法确定ELISA的最佳工作浓度,建立标准曲线。在0.75~300 ng/L范围内,抑制率与PCB77的质量浓度对数呈显著的线性关系,检测限达到4.44μg/L。结论:合成的PCB77人工抗原具有较好的免疫效果,纯化后的抗体符合后续实验的条件要求,为研制和开发PCB77免疫检测试剂盒奠定了基础。     

甲氰菊酯人工抗原的合成和鉴定

目的 合成与鉴定甲氰菊酯的人工抗原.方法 通过水解、酰化、酯化等反应合成了甲氰菊酯的半抗原2,2,3,3.四甲基环丙烷羧酸-a-(N-丁酸基)-甲酰氨-3-苯氧基苄酯(Ⅳ)和2,2,3,3-四甲基环丙烷羧酸-a-羧基-3-苯氧基苄酯(Ⅲ).通过碳二亚胺法将半抗原Ⅳ与牛血清蛋白(BSA)偶联制备免疫抗原,通过混合酸酐法将半抗原Ⅲ与卵清蛋白(OVA)偶联制备包被抗原.结果 用质谱和核磁共振对Ⅲ和Ⅳ进行结构表征,合成产物为目标物.紫外光谱法鉴定结果表明,免疫抗原和包被抗原都发生了有效偶联,偶联比38:1和15:1,免疫抗原通过免疫新西兰大白兔得到的抗体效价为5.12×105.结论成功的合成了甲氰菊酯的人工抗原,为其免疫方法的建立奠定了基础.     

女性弥漫性脱发患者的微量营养素分析

目的 对三种类型的女性弥漫性脱发患者的微量营养素水平进行分析。方法 回顾性分析2018年1月至2021年6月就诊于大坪医院皮肤性病科门诊的299例不同类型女性弥漫性脱发患者的临床资料。结果 弥漫性脱发患者血清25-羟基维生素D和铁蛋白水平均显著低于对照组,且与弥漫性脱发的类型无关;弥漫性斑秃患者血清锌浓度也显著低于对照组。分别以铁蛋白≤50 ng/mL为铁缺乏的界限值,以25-羟基维生素D≤20 ng/mL作为血清25-羟基维生素D缺乏的界限时,三种类型的弥漫性脱发患者血清25-羟基维生素D和血清铁蛋白缺乏的比例均高于对照组(P<0.05)。即缺乏铁和血清25-羟基维生素D与女性弥漫性脱发的发生有关。结论 铁代谢障碍和血清25-羟基维生素D水平在女性弥漫性脱发中起关键作用,而铜和锌对头发生长和脱发周期的影响仍需进一步研究。     

氯霉素-BSA和氯霉素-OVA偶联物的制备与鉴定

目的：制备氯霉素（CAP）-牛血清闩蛋白（BSA）及氯霉素（CAP）-卵清白蛋白（OVA）的偶联物并进行鉴定。方法：分别采用混合酸酐法和重氮化法制备CAP—BSA及CAP—OVA的偶联物，前者是将CAP先与琥珀酸酐反应生成CAP-半琥珀酸酯（CAP—HS），再进行混合酸酐反应。将反应产物CAP—HS与BSA结合，合成CAP—HS—BSA偶联物；后者是将CAP分子中的苯环上的硝基还原为氯基后，进行重氮化处理，然后分别与BSA和OVA连接，合成CAP—BSA和CAP—OVA复合物。结果：紫外图谱分析表明，CAP—BSA、CAP—OVA和CAP—HS—BSA的紫外最大吸收峰分别是262nm、213nm和275nm；计算得CAP与载体蛋白BSA、OVA及HS的偶联比分别为5：1、12：1和22：1。结论：成功的制备CAP—BSA及CAP—OVA的偶联物，为免疫动物制备抗CAP的抗体奠定了基础。     

改变半抗原与载体间隔臂的长度对环丙沙星抗体特性的影响

目的在用乙二胺(ethanediamine,EDA)化牛血清白蛋白(BSA)为载体合成环丙沙星(ciprofloxacin,CIP)免疫原已制备了高特异性抗体(IC50达1 ng/ml)的基础上,尝试延长间隔臂长度,以己二胺(hexamethylenediamine,HMD)进一步修饰BSA合成免疫原制备抗血清,探索其对环丙沙星抗体灵敏度及特异性的影响。方法以己二胺修饰BSA,合成环丙沙星免疫原,免疫Balb/c小鼠制备多克隆抗体,同时以天然、乙二胺及己二胺化鸡卵清白蛋白(OVA)为载体合成包被原CIP-OVA、CIP-EDA-OVA和CIP-HMD-OVA,用间接竞争酶联免疫检测方法(ic-ELISA)对抗血清进行评价。结果获得了更高特异性的环丙沙星抗血清,IC50达0.1 ng/ml,抗体的交叉反应性也明显降低,且与CIP-EDA-OVA、CIP-HMD-OVA包被原相比,以CIP-OVA为包被原可显著提高环丙沙星ELISA灵敏度。结论改变抗原间隔臂长度对特异性抗体的产生有较大影响,且改变包被原间隔臂的结构可显著提高ELISA的灵敏度。     

中药补肾活骨方对去势骨质疏松大鼠骨代谢的影响

背景：中药补肾活骨方可有效防治骨质疏松症,但其具体的药理学机制仍不是很清楚。25-羟基维生素D3和1,25-二羟基维生素D3是调节骨吸收与骨形成的重要的偶联因子。 目的：观察补肾中药对去势骨质疏松大鼠骨密度、骨生物力学、血清及肝肾组织中25-羟基维生素D3和1,25-二羟基维生素D3水平的影响。 方法：健康雌性SD大鼠108只随机等分为假手术组、模型组和治疗组。后2组摘除双侧卵巢,导致雌激素缺失,从而诱导骨质疏松症模型。治疗组大鼠造模后以中药补肾活骨方2 mL灌胃,2次/d。 结果与结论：与模型组相比,治疗组股骨头骨密度明显提高(P < 0.05),最大应力和最大负荷指数明显增强(P < 0.05),血液、肝脏和肾脏组织中25-羟基维生素D3和1,25 二羟基维生素D3水平明显提高(P < 0.05);且接近于假手术组(P < 0.05)。提示补肾中药在雌激素缺失早期即可在分子水平上调节25-羟基维生素D3和1,25-二羟基维生素D3的表达水平,激活骨代谢提高骨密度增强骨质量达到预防骨质疏松的作用。关键词：补肾活骨方;1,25-二羟基维生素D3;骨密度;骨生物力学;骨质疏松症;骨代谢 doi:10.3969/j.issn.1673-8225.2012.15.006 中图分类号: R318  文献标识码: A       

大黄素-BSA包被膜片人工抗原制备及其免疫原性与特异性检测

目的:通过大黄素-BSA包被膜片的免疫原性及特异性研究,探讨半抗原-载体包被膜片人工抗原制备法的可行性。方法:先将BSA包被于PVDF膜片,再与大黄素-偶联剂衍生物偶联,制备大黄素-BSA包被膜片,经膜片皮下包埋法免疫大鼠,用大黄素或大黄酚、大黄素甲醚包被CA膜片免疫分析法检测免疫原性和特异性。结果:大黄素-BSA包被膜片的免疫原性高于或等于液相抗原;其抗血清对三种蒽醌类化合物反应的特异性基本一致(P0.05)。结论:大黄素-BSA包被膜片抗原,具有良好免疫原性和特异性,提示用半抗原-载体包被膜片法制备人工抗原可行。     

大黄素-BSA不同表位构型的免疫原性和特异性研究

目的:研究不同偶联法制备大黄素-BSA的大黄素表位构型及其免疫原性和特异性。方法:用重氮化对氨基苯甲酸偶联法和琥珀酸酐偶联法制备两种不同表位构型的大黄素-BSA1和大黄素-BSA2抗原,免疫小鼠制备抗血清,用醋酸纤维素膜双向免疫扩散法检测免疫原性及其抗体特异性。结果:大黄素-BSA1和大黄素-BSA2抗血清与大黄素反应的抗体效价分别为1∶144 0±357.771和1∶440±219.089,二者有极显著性差异(P=0.006)。分别与大黄素等五种蒽醌类化合物反应,前者对大黄素有较高特异性,抗原结合效价可达1∶1 843.2±457.947。后者对大黄素的特异性较低,结合效价仅为1∶8.8±4.382。结论:两种偶联法制备大黄素-BSA的表位构型不同,其免疫原性和特异性存在着显著差异。重氮化对氨基苯甲酸偶联法制备大黄素-BSA的免疫原性较高、大黄素特异性较强。     

维生素D水平与2型糖尿病合并抑郁症相关性研究

目的 测定2型糖尿病合并抑郁症患者血清25-羟维生素D3水平,探讨维生素D缺乏与2型糖尿病合并抑郁症的关系。方法 选择2015年9月~2017年3月于我院住院的2型糖尿病患者84例,根据HAMD评分将患者分为T2DM组44例和T2DMD组40例。收集两组患者临床资料,检测FBG、HbA1c、TC、TG、LDL-C、HDL-C、血清25-羟维生素D3水平,进行Pearson相关分析和Logistic回归分析,并比较两组患者血清25-羟维生素D3缺乏患病率。结果 两组患者年龄、BMI、TC、TG比较,差异无统计学意义（P＞0.05）;T2DMD组FBG、HbA1c、LDL-C均高于T2DM组,且糖尿病病程长于T2DM组,差异具有统计学意义（P＜0.05）。T2DM组血清25-羟维生素D3平均水平为（20.94±1.68）ng/ml,高于T2DMD组的（16.44±2.05）ng/ml,差异具有统计学意义（P＜0.05）。T2DMD组血清25-羟维生素D3缺乏患病率为95.00%,高于T2DM组的31.82%,差异具有统计学意义（P＜0.05）。Pearson相关分析显示,血清25-羟维生素D3水平与FBG、HbA1c、LDL-C、病程均呈负相关（P＜0.05）,与HDL-C呈正相关（P＜0.05）,与BMI、TC及TG均无相关性（P＞0.05）。多元Logistic回归分析显示,血清25-羟维生素D3水平、FBG、HbA1c及病程是2型糖尿病合并抑郁症的独立危险因素（P＜0.05）。结论 2型糖尿病合并抑郁症患者维生素D缺乏更加普遍,维生素D缺乏可能参与2型糖尿病合并抑郁症的发病过程。     

HBeAg阴性慢性乙型肝炎患者血清25-羟基维生素D3的检测及临床意义

目的 探究HBeAg阴性慢性乙型肝炎患者血清25-羟基维生素D3的水平变化及临床意义。方法 选取2015年3月~2018年5月81例HBeAg阴性且非肝硬化的慢性乙型肝炎患者作为观察组,依据血清谷丙转氨酶（ALT）水平分为观察组A 41例（ALT处于正常水平且HBV DNA水平＜2000 IU/ml,持续时间高于6个月）和观察组B 40例（ALT处于升高水平且HBV DNA水平≥2000 IU/ml,持续时间高于6个月）。同时选取同期健康体检人群40例作为对照组。分别检测三组血清25-羟基维生素D3的浓度。结果 观察组血清25-羟基维生素D3低于健康人群,统计学意义显著（P＜0.001）,三组间比较,统计学意义显著（P＜0.001）。观察组患者血清25-羟基维生素D3与年龄、BMI、ALT、AST、Hb、WBC、PLT及AFP均无明显相关性（P＞0.05）。而与HBV DNA含量间存在显著负相关（r=-3.981,P＜0.05）。结论 HBeAg阴性慢性乙型肝炎患者血清25-羟基维生素D3存在异常,并与乙肝病毒复制相关,可能参与机体和乙肝病毒的免疫反应过程。     

Vitamin D status in patients with Behcet's Disease

OBJECTIVES:

This study investigated the serum 25-hydroxyvitamin D levels of patients with Behcet''s Disease.

DESIGN AND METHODS:

Thirty-two patients with Behcet''s Disease and 31 matched healthy controls were enrolled in this study. The erythrocyte sedimentation rate (ESR) and the levels of C-reactive protein (CRP), serum 25-hydroxyvitamin D, calcium (Ca), phosphate (P), and total alkaline phosphatase (ALP) were measured in both groups.

RESULTS:

There were no significant differences between the two groups regarding demographic data. The serum 25-hydroxyvitamin D levels of patients and controls were 13.76 (range: 4.00-35.79) and 18.97 (range: 12.05-36.94) ng/ml, respectively. In patients with Behcet''s Disease, 25-hydroxyvitamin D values were significantly lower than those of the healthy controls (p<0.001). Serum Ca, P, and ALP levels were similar in both groups. Serum ESR and CRP levels were significantly higher in patients than controls (p<0.05). There was no correlation between 25-hydroxyvitamin D levels and age, body mass index (BMI), disease duration, ESR, or CRP levels. Multivariate regression analysis parameters showed that smoking, alcohol intake, and use of colchicine were the main predictors of 25-hydroxyvitamin D levels. Of the parameters studied, the largest impact was due to colchicine therapy (p<0.001). We did not find a significant relationship between the use of corticosteroids and 25-hydroxyvitamin D levels.

CONCLUSION:

Our results suggest that serum 25-hydroxyvitamin D levels are decreased in patients with Behcet''s Disease. Smoking, alcohol intake, and use of colchicine appear to affect vitamin D levels.     

Treatment of hypoparathyroidism and pseudohypoparathyroidism with metabolites of vitamin D: evidence for impaired conversion of 25-hydroxyvitamin D to 1 alpha,25-dihydroxyvitamin D.

In hypoparathyroidism and pseudohypoparathyroidism, pharmacologic doses of vitamin D correct hypocalcemia, but the mechanism is unknown. In two children with hypoparathyroidism and one with pseudohypoparathyroidism we tested the hypothesis that in these conditions there is a defect in synthesis of 1 alpha,25-dihydroxyvitamin D3, the principal active metabolite of vitamin D. In both conditions, minute doses of the metabolite (0.04 to 0.08 mug per kilogram of body weight per day) quickly corrected hypocalcemia and increased intestinal calcium absorption. On the other hand, the effective dose of 25-hydroxyvitamin D3 to maintain normocalcemia was 3 to 4 mug per kilogram per day in the two conditions. Thus, the dosage ratio of 25-hydroxyvitamin D3 to 1 alpha,25-dihydroxyvitamin D3 approximated 100:1. By contrast this ratio was approximately 3:1 in two infants with vitamin D deficiency, a condition in which optimal metabolism of vitamin D would be expected. These findings suggest an impaired conversion of 25-hydroxyvitamin D to 1 alpha,25-dihydroxyvitamin D in both hypoparathyroidism and pseudohypoparathyroidism.     

孕妇血清维生素A、维生素E、25-羟基维生素D与 子痫前期的相关性研究

目的 探讨孕妇血清维生素A、维生素E、25-羟基维生素D水平与子痫前期的相关性。方法 选择2016年3月~2017年10月在我院产检的单胎孕妇为研究对象,其中子痫前期组72例,健康对照组30例。分析血清维生素A、维生素E、25-羟基维生素D水平与子痫前期的相关性及其诊断价值。结果 在孕10~14周时,两组孕妇孕血清维生素A、维生素E 、25-羟基维生素D水平比较,差异无统计学意义（P＞0.05）;孕24~28周时,子痫前期组血清维生素A、维生素E 、25-羟基维生素D水平低于对照组水平（P＜0.05）;多因素Logistic回归分析结果显示,孕24~28周血清维生素A、维生素E、25-羟基维生素D水平与子痫前期发病具有显著的相关性;回归模型显示,血清维生素A诊断子痫前期的AUC为0.976,95%CI为0.931~1.000,当界值为0.46时,预测子痫前期发病的灵敏度为95.70%,特异度为72.50%;维生素E诊断子痫前期的AUC为0.820,95%CI为0.725~0.914,当界值为0.28时,预测子痫前期发病的灵敏度为76.70%,特异度为77.80%;25-羟基维生素D诊断子痫前期的AUC为0.789,95%CI为0.681~0.898,当界值为0.33时,预测子痫前期发病的灵敏度为73.30%,特异度为81.90%;血清维生素A+维生素E+25-羟基维生素D诊断子痫前期的AUC为0.988,95%CI为0.966~1.000。当界值为0.55时,预测子痫前期发病的灵敏度为96.70%,特异度为95.80%。结论 在孕10~14周时,血清维生素A、维生素E、25-羟基维生素D水平下降与子痫前期发病无关;在孕24~28周时,血清维生素A、维生素E、25-羟基维生素D水平下降与子痫前期发病显著相关,孕晚期血清维生素A、维生素E、25-羟基维生素D可作为子痫前期的关键指标。     

Influence of estrogen on renal vitamin D hydroxylases and serum 1alpha,25-(OH)2D3 in chicks.

The influence of estrogen on the metabolism of 25-hydroxyvitamin D3 was studied in 2- to 5-wk-old chicks. Single injections of at least 500 microgram diethylstibestrol (DES) increased the conversion of 25-hydroxyvitamin D3 to 1alpha,25-dihydroxyvitamin D3 (1alpha,25-(OH)2D3) and suppressed the production of 24,25-dihydroxyvitamin D3 in chick kidney homogenates. Acute (one 5-mg) injections of testosterone or progesterone did not enhance the 25-hydroxyvitamin D3-1alpha-hydroxylase, indicating specificity. However, chronic pretreatment with DES appeared to allow the potentiation of previously unstimulatory steroids such as progesterone and testosterone. In addition, the hormonal metabolite of vitamin D3, 1alpha,25-(OH)2D3, was measured in 4- to 6-wk chick plasma after steroid treatment. Greater than 1 mg DES per day for 5 days was necessary to enhance the circulating level of 1alpha,25-(OH)2D3; testosterone alone had no effect. This elevation was rapid, occurring within 12--24 h after injection. These data suggest that estrogen (as evidenced by DES treatment) is a modulator of vitamin D metabolism along with other known regulators such as parathyroid hormone, phosphate, and 1alpha,25-(OH)2D3. The mechanism of the regulation is as yet unknown.     

The oxidant and antioxidant effects of 25-hydroxyvitamin D3 in liver, kidney and heart tissues of diabetic rats

Abstract Previous studies have implicated protective effects of vitamin D on insulin secretion and pancreas cell function. The goal of the present study is to determine if a combination therapy of 25-hydroxyvitamin D3 and insulin had any advantage over insulin therapy alone on lipid peroxidation and antioxidant activity in the streptozotocin (STZ)-induced diabetic rat. The lipid peroxidation product, thiobarbituric acid-reacting substances (TBARS), was measured to assess free radical activity in the heart, kidney and liver tissues. The enzymatic activities of glutathione peroxidase (GSH-Px), superoxide dismutase (SOD) and catalase (CAT) were measured as indicators of antioxidation in these tissues. Sprague-Dawley rats were made diabetic with a single injection of STZ (75 mg/kg i.p.). Rats were separated into three groups, each containing 10 animals: Group 1, non-diabetic and no drug treatment was given; Group 2, diabetic rats were treated with 3 IU/day subcutaneous (s.c.) insulin; and Group 3, diabetic rats were treated with 3 IU/day (s.c.) insulin plus 1 mg/kg/day per oral (p.o.) 25-hydroxyvitamin D3 for a period of 4 weeks. At the end of the study, TBARS contents of the liver, kidney and heart tissues in Groups 2 and 3 were found to be significantly increased as compared to Group 1 (P<0.05) and kidney MDA levels in Group 3 were also significantly increased as compared to Group 2 (P<0.05). The SOD and CAT contents of the heart in Group 2 were significantly increased as compared to Groups 1 and 3 (P<0.05). GSH-Px activity was unaltered in all groups (P>0.05). We suggest that a combination of insulin with 25-hydroxyvitamin D3 treatment would not be more beneficial than the use of insulin alone in antioxidant defence of diabetic liver and kidney tissues.     

Rapid and sensitive high-performance liquid chromatographic method for simultaneous determination of retinol, alpha-tocopherol, 25-hydroxyvitamin D3 and 25-hydroxyvitamin D2 in human plasma with photodiode-array ultraviolet detection

A new rapid and sensitive high-performance liquid chromatographic method using 0.5 ml of plasma has been developed for the simultaneous determination of retinol (vitamin A), alpha-tocopherol (vitamin E), 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3. The eluate was monitored with a photodiode-array detector with two fixed wavelengths (267 nm for vitamin D, 292 nm for alpha-tocopherol and retinol). For all compounds, including internal standards, the method provides extraction recoveries greater than 81%. Detection limits were equal to or lower than 1.5 microg/l for the 4 vitamins. Linearity of standards was excellent (r>0.999 in all cases). Intra-day and inter-day precision were generally acceptable; the intra-dayassay C.V. was 3/4 7.7 for all compounds and the inter-day-assay C.V. was <9.2% except for the lower concentrations of 25-hydroxyvitamin D3, 25-hydroxyvitamin D2 and alpha-tocopherol (10.8, 11.8 and 11.9, respectively). The important properties of the present method are its ease of use, its rapidity, since sample preparation was achieved in 15 min and all the compounds were eluted in less than 15 min, and its small sample volume required (=0.5 ml), which enables it to be used in pediatric practice.     

Phase IB study of 25-hydroxyvitamin D(3) treatment to diminish suppressor cells in head and neck cancer patients.

Patients with head and neck squamous cell carcinoma (HNSCC) have profound immune defects. These defects are associated with a poor prognosis and are mediated, in part, by an increased number of immune inhibitory CD34(+) progenitor cells in their peripheral blood and tumor. The CD34(+) cells suppress autologous T-cell functions. Our prior work had shown that the differentiation inducer 1alpha,25-dihydroxyvitamin D(3) could drive the differentiation of CD34(+) cells isolated from HNSCC patients into dendritic cells. A phase IB clinical trial was initiated with HNSCC patients to determine if 25-hydroxyvitamin D(3) treatment could diminish CD34(+) cell levels and improve immune function. Six patients per treatment group were orally administered 20 or 40 microg/day 25-hydroxyvitamin D(3) for six weeks. Peripheral blood was collected at 0, 1, 2, 4, 6, and 8 weeks, and assessed for markers of immune activity. Although no clinical responses were observed, results of these pilot studies showed that 25-hydroxyvitamin D(3) reduced the presence of immune suppressive CD34(+) cells and improved immune competence of HNSCC patients.     

原发性肝癌患者血清25-羟基维生素D3水平与免疫抑制因子IL-10的关系

目的 探究原发性肝癌患者血清25-羟基维生素D3[25-（OH）D3]的变化及其与免疫抑制因子IL-10的关系。方法 选取2014年2月~2019年7月于我院就诊的60例原发性肝癌患者作为疾病组,另外选择同期60名健康体检人群作为健康对照组,采用电化学发光法测定两组血清25-（OH）D3浓度,酶联免疫吸附试验测定血清IL-10浓度。Spearman法分析25-（OH）D3与IL-10间的相关性。结果 疾病组血清25-（OH）D3浓度低于健康对照组[（13.65±7.92）ng/ml vs （26.15±8.33）ng/ml],差异有统计学意义（P＜0.05）;疾病组IL-10浓度高于健康对照组[（89.71±26.59）ng/ml vs （26.18±8.15）ng/ml],差异有统计学意义（P＜0.05）。血清25-（OH）D3可能与淋巴结转移和肿瘤分期密切相关,与IL-10浓度呈负相关（r=-0.568,P＜0.05）。结论 原发性肝癌患者存在25-（OH）D3缺乏现象,且与肿瘤进展和免疫抑制密切相关。